725,000 Shares in Revance Therapeutics, Inc. (NASDAQ:RVNC) Purchased by Oddo BHF Asset Management Sas

Oddo BHF Asset Management Sas purchased a new position in Revance Therapeutics, Inc. (NASDAQ:RVNC) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 725,000 shares of the biopharmaceutical company’s stock, valued at approximately $3,763,000. Oddo BHF Asset Management Sas owned approximately 0.69% of Revance Therapeutics as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also modified their holdings of RVNC. Alpine Associates Management Inc. acquired a new stake in Revance Therapeutics during the third quarter valued at approximately $21,605,000. Stonepine Capital Management LLC raised its stake in Revance Therapeutics by 41.7% during the second quarter. Stonepine Capital Management LLC now owns 2,800,000 shares of the biopharmaceutical company’s stock valued at $7,196,000 after buying an additional 823,658 shares in the last quarter. State Street Corp raised its stake in Revance Therapeutics by 6.6% during the third quarter. State Street Corp now owns 2,433,963 shares of the biopharmaceutical company’s stock valued at $12,632,000 after buying an additional 150,323 shares in the last quarter. LMR Partners LLP acquired a new stake in Revance Therapeutics during the third quarter valued at approximately $11,648,000. Finally, Federated Hermes Inc. raised its stake in Revance Therapeutics by 43.0% during the second quarter. Federated Hermes Inc. now owns 2,237,505 shares of the biopharmaceutical company’s stock valued at $5,750,000 after buying an additional 672,803 shares in the last quarter. Institutional investors and hedge funds own 97.70% of the company’s stock.

Revance Therapeutics Stock Performance

RVNC opened at $3.08 on Friday. The stock has a fifty day moving average of $4.60 and a 200-day moving average of $4.46. Revance Therapeutics, Inc. has a 12-month low of $2.30 and a 12-month high of $9.74.

Revance Therapeutics (NASDAQ:RVNC) last released its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.02). The firm had revenue of $59.88 million during the quarter, compared to the consensus estimate of $67.73 million. On average, sell-side analysts anticipate that Revance Therapeutics, Inc. will post -1.57 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the company. Needham & Company LLC reaffirmed a “hold” rating on shares of Revance Therapeutics in a report on Friday, November 8th. HC Wainwright reaffirmed a “neutral” rating and set a $6.60 price target on shares of Revance Therapeutics in a research note on Friday, November 8th. Barclays reaffirmed an “equal weight” rating and set a $7.00 price target (down from $10.00) on shares of Revance Therapeutics in a research note on Friday, September 13th. Mizuho decreased their price target on Revance Therapeutics from $6.66 to $3.10 and set a “neutral” rating for the company in a research note on Tuesday. Finally, StockNews.com began coverage on Revance Therapeutics in a research note on Thursday. They set a “hold” rating for the company. Nine analysts have rated the stock with a hold rating and one has given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $8.96.

Revance Therapeutics Profile

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.